Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-19
2011-07-19
Romeo, David S (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S008500, C530S399000, C424S094100
Reexamination Certificate
active
07981864
ABSTRACT:
Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion proteins that include an IGF targeting moiety are transported to neural tissue in the brain from blood. Methods and compositions of the invention include therapeutic applications for treating lysosomal storage diseases. The invention also provides nucleic acids and cells for expressing IGF fusion proteins.
REFERENCES:
patent: 4309776 (1982-01-01), Berguer
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4749570 (1988-06-01), Poznansky
patent: 4801575 (1989-01-01), Pardridge
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5258453 (1993-11-01), Kopecek et al.
patent: 5356804 (1994-10-01), Desnick et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5405942 (1995-04-01), Bell et al.
patent: 5470828 (1995-11-01), Ballard et al.
patent: 5476779 (1995-12-01), Chen et al.
patent: 5549892 (1996-08-01), Friedman et al.
patent: 5580757 (1996-12-01), Desnick et al.
patent: 5633234 (1997-05-01), August et al.
patent: 5633235 (1997-05-01), Townsend et al.
patent: 5704910 (1998-01-01), Humes
patent: 5736363 (1998-04-01), Edwards et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 5817623 (1998-10-01), Ishii
patent: 5817789 (1998-10-01), Heartlein et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5854025 (1998-12-01), Edwards et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 5981194 (1999-11-01), Jefferies et al.
patent: 6020144 (2000-02-01), Gueiros-Filho et al.
patent: 6027921 (2000-02-01), Heartlein et al.
patent: 6066626 (2000-05-01), Yew et al.
patent: 6083725 (2000-07-01), Selden et al.
patent: 6118045 (2000-09-01), Reuser et al.
patent: 6226603 (2001-05-01), Freire et al.
patent: 6235874 (2001-05-01), Wu et al.
patent: 6262026 (2001-07-01), Heartlein et al.
patent: 6270989 (2001-08-01), Treco et al.
patent: 6273598 (2001-08-01), Keck et al.
patent: 6281010 (2001-08-01), Gao et al.
patent: 6284875 (2001-09-01), Turpen et al.
patent: 6329501 (2001-12-01), Smith et al.
patent: 6344436 (2002-02-01), Smith et al.
patent: 6348194 (2002-02-01), Huse et al.
patent: 6441147 (2002-08-01), Turpen et al.
patent: 6451600 (2002-09-01), Rasmussen et al.
patent: 6455494 (2002-09-01), Jefferies et al.
patent: 6472140 (2002-10-01), Tanzi et al.
patent: 6537785 (2003-03-01), Canfield
patent: 6566099 (2003-05-01), Selden et al.
patent: 6569661 (2003-05-01), Qin et al.
patent: 6596500 (2003-07-01), Kang et al.
patent: 7396811 (2008-07-01), LeBowitz et al.
patent: 2001/0006635 (2001-07-01), Bennett et al.
patent: 2001/0025026 (2001-09-01), Heartlein et al.
patent: 2002/0013953 (2002-01-01), Reuser et al.
patent: 2002/0081654 (2002-06-01), Sandrin et al.
patent: 2002/0110551 (2002-08-01), Chen
patent: 2002/0142299 (2002-10-01), Davidson et al.
patent: 2003/0004236 (2003-01-01), Meade
patent: 2003/0021787 (2003-01-01), Hung et al.
patent: 2003/0077806 (2003-04-01), Selden et al.
patent: 2003/0082176 (2003-05-01), LeBowitz et al.
patent: 2004/0005309 (2004-01-01), LeBowitz et al.
patent: 2004/0006008 (2004-01-01), LeBowitz et al.
patent: 2004/0029779 (2004-02-01), Zhu et al.
patent: 2004/0081645 (2004-04-01), Van Bree et al.
patent: 2004/0248262 (2004-12-01), Koeberl et al.
patent: 2005/0026823 (2005-02-01), Zankel et al.
patent: 2005/0058634 (2005-03-01), Zhu
patent: 2005/0281805 (2005-12-01), LeBowitz et al.
patent: 0196056 (1986-10-01), None
patent: 0466222 (1992-01-01), None
patent: 0599303 (1994-06-01), None
patent: WO-9104014 (1991-04-01), None
patent: WO-9114438 (1991-10-01), None
patent: WO-9222332 (1992-12-01), None
patent: WO-9306216 (1993-04-01), None
patent: WO-9310819 (1993-06-01), None
patent: WO-9402178 (1994-02-01), None
patent: WO-9502421 (1995-01-01), None
patent: WO-0053730 (2000-09-01), None
patent: WO-0119955 (2001-03-01), None
patent: WO-0153730 (2001-07-01), None
patent: WO-0244355 (2002-06-01), None
patent: WO-02056907 (2002-07-01), None
patent: WO-02087510 (2002-11-01), None
patent: WO-03032727 (2003-04-01), None
patent: WO-03032913 (2003-04-01), None
patent: WO-03057179 (2003-07-01), None
patent: WO-03102583 (2003-12-01), None
patent: WO-2005078077 (2005-08-01), None
Bagley et al. Biochem J. May 1, 1989; 259(3): 665-671.
“Purification,” The QlAexpressionist, pp. 63-107 (2001).
“QIAexpress Protein Purification System”QIAexpress—The Complete System for 6xHis Technology pp. 7-12, (2001).
Achord et al., “Human β-Glucuronidase. II. Fate of Infused Human Placental β-Glucuronidase in the Rat,” Pediat. Res., 11:816-822 (1977).
Achord, et al., “Human β-Glucuronidase: In Vivo Clearance and in Vitro Uptake by a Glycoprotein Recognition System on Reticuloendothelial Cells” Cell, 15:269-278 (1978).
Aeed and Elhammer, “Glycosylation of recombinant prorenin in insect cells: the insect cell line Sf9 does not express the mannose 6-phosphate recognition signal. Glycosylation of recombinant prorenin in insect cells: the insect cell line Sf9 does not express the mannose”, Biochemistry, 33(29):8793-0797 (1994).
Aerts et al., “Efficient Routing of Glucocerebrosidase to Lysosomes Requires Complex Oligosaccharide Chain Formation,” Biochem. Biophys. Res. Commun., 141(2):452-458 (1986).
Allen et al., “Metabolic Correction of Fucosidosis Lymphoid Cells by Galaptin-α-L-Fucosidase Conjugates,” Biochem. Biophys. Res. Communi., 172(1):335-340 (1990).
Amalfitano et al., “Recombinant Human Acid Alpha-Glucosidase Enzyme Therapy for Infantile Glycogen Storage Disease Type II: Results of a Phase I/II Clinical Trial,” Genet. Med. 3(2):132-138 (2001).
Anand, “The Cure”, HarperCollins, New York, NY, Chapter 23, pp. 257-268 (2006).
Arai et al., “Conformations of Variably Linked Chimeric Proteins Evaluated by Synchrotron X-ray Small-Angle Scattering,” Proteins: Structure, Function, and Bioinformatics, 57:829-838 (2004).
Armstrong et al., “Uptake of Circulating Insulin-Like Growth Factor-I Into the Cerebrospinal Fluid of Normal and Diabetic Rats and Normalization of 1GF-II mRNA Content in Diabetic Rat Brain,” Journal of Neuroscience Research, 59:649-660 (2000).
Auletta et at, “Receptor-mediated endocytosis and degradation of insulin-like growth factor I and II in neonatal rat astrocytes”, Journal of Neuroscience Research, 31:14-20 (1992).
Authier et al., “In vitro endosome-lysosome transfer of dephosphorylated EGF receptor and Shc in rat liver,” FEBS Letters, 00:25-31 (1999).
Bach et al., “Binding of Mutants of Human Insulin-like Growth Factor II to Insulin-like Growth Factor Binding Proteins 1-6,” J. Biol. Chem., 268(12):9246-9254 (1993).
Bartlett et al., “CAVEAT: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules,” in Molecular Recognition: Chemical and Biological Problems, 182-196 (1989).
Barton et al., “Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease,” Proc Natl Acad Sci USA, 85(5):1913-1916 (Mar. 1990).
Baxter, “Insulin-like Growth Factor (IGF)-Binding Proteins: Interactions with IGFs and Intrinsic Bioactivities.” Am. J. Physiol. Endocrinol. Metab., 278(6)967-976 (2000).
Becker et al., “HLA and Mate Choice,” J. Hum. Genet., 62:991 (1998).
Beljaars et al., “Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P28-HSA),” Liver, 21:320-328 (2001).
Beutler et al., “Gaucher Disease,” in The Metabolic and Molecular Bases of Inherited Disease, 8thed., 3635-3668 (2001).
Bickel et al., “Delivery of Peptides and Proteins through the Blood-Brain Barrier,” Advanced Drug Delivery Reviews 4
Biomarin Pharmaceutical Inc.
Gamett Daniel C
Marshall Gerstein & Borun
Romeo David S
LandOfFree
Methods and compositions for targeting proteins across the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for targeting proteins across the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for targeting proteins across the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702887